Filing Flows › Supernus Pharmaceuticals (SUPN) › Q2 2026
Supernus Pharmaceuticals (SUPN) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 3, 2026
Supernus Pharmaceuticals (SUPN) reported revenue of $219M for the second quarter 2026 (Q2 2026), +32% from a year earlier and +5% from the quarter before. Operating margin was -26.5%, net loss $58.4M (26.6% of revenue).
Supernus Pharmaceuticals, Q2 2026: revenue $219M (+32% year over year), operating margin -26.5%, net loss $58.4M, operating cash flow −$4.8M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $219M | +5% | +32% |
| Operating profit | −$58.0M | — | -577% |
| Net earnings | −$58.4M | — | -359% |
| Operating cash flow | −$4.8M | -107% | -108% |
What changed
Revenue was $219.1M in Q2 2026, up 32% year over year and up 5% from the previous quarter. Qelbree was the largest line at 41% of revenue. ONAPGO added $11.9M year over year (up 745%), 22% of the total change. Other declined 71%.
Operating costs exceeded revenue by $58.0M, an operating margin of -26.5%. Total costs grew 81% against revenue growth of 32%. The fastest-growing cost line was Other operating costs (+285%). The quarter ended with a net loss of $58.4M, wider than the previous quarter's $2.3M loss.
Operating cash flow was −$4.8M. Non-cash charges added back $25.7M of depreciation and amortization and $8.6M of share-based compensation. Working capital and other items added $19.2M. Capital expenditures of $568K exceeded it, leaving free cash flow of −$5.4M.
Questions
What was Supernus Pharmaceuticals' revenue in the second quarter 2026?
Supernus Pharmaceuticals (SUPN) reported revenue of $219M for the second quarter 2026 (Q2 2026), +32% from a year earlier and +5% from the quarter before.
Was Supernus Pharmaceuticals profitable in the second quarter 2026?
Operating loss was $58.0M (-26.5% of revenue) and net loss $58.4M.